Your AI-Trained Oncology Knowledge Connection!

Anjali Advani, MD

home / authors / anjali-advani-md

Articles

Harry Erba, MD, PhD, an expert on leukemia

Acute Myeloid Leukemia: Updates From The ASH 2022 Annual Meeting

Sameem Abedin, MD;Elias Jabbour, MD;Harry Erba, MD, PhD;Anjali Advani, MD

February 14th 2023

Shared insight on recently updated data in acute myeloid leukemia following the ASH 2022 annual meeting.

Anjali Advani, MD, an expert on leukemia

ASH 2022: Recent Advances in Chronic Myeloid Leukemia

Sameem Abedin, MD;Elias Jabbour, MD;Harry Erba, MD, PhD;Anjali Advani, MD

February 14th 2023

Experts in hematologic oncology review and analyze updated data in chronic myeloid leukemia from ASH 2022.

Elias Jabbour, MD, an expert on leukemia

ASH 2022: Updates in the Acute Lymphocytic Leukemia Treatment Landscape

Sameem Abedin, MD;Elias Jabbour, MD;Harry Erba, MD, PhD;Anjali Advani, MD

February 14th 2023

Following the ASH 2022 Annual Meeting, hematologic oncology experts discuss updated data in acute lymphocytic leukemia.

Dr. Advani Compares Inotuzumab and Blinatumomab for ALL

Anjali Advani, MD

January 8th 2015

Anjali Advani, MD ,staff physician, Department of Hematologic Oncology and Blood Disorders, Director, Inpatient Leukemia Program, Taussig Cancer Institute, associate professor, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, compares inotuzumab ozogamicin, a CD22 monoclonal antibody, to blinatumomab, a CD19 bi-specific anti-CD19/CD3 antibody for the treatment of acute lymphoblastic leukemia (ALL).